Silo Pharma is focused on creating novel therapeutics and advanced drug delivery systems targeting underserved conditions within central nervous system diseases, stress-induced psychiatric disorders and chronic pain management.
Assets:
SPC-15: Silo’s lead asset is a nose-to-brain intranasal prophylactic treatment targeting Post-Traumatic Stress Disorder and stress-induced anxiety disorders.
SP-26: A time-release, ketamine-loaded implant designed for chronic pain relief and fibromyalgia.
Preclinical Programs:
SPC-14 – An intranasal treatment targeting Alzheimer’s disease
SPU-16 – A CNS-homing peptide targeting multiple sclerosis.
NEWS & PARTNERSHIPS
2022
The company was awarded US Patent No. 11,491,120 for its lead asset, SPC-15.
2023
The company announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions.
The company entered into an exclusive licensing agreement with Medspray Pharmafor its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.
2024
The company expanded its intellectual property by officially exercising its option to secure an exclusive, global license with Columbia University (building on a 2021 research agreement). This grants the company worldwide rights to develop, manufacture, and commercialize SPC-15 as a prophylactic treatment for stress-induced affective disorders, including PTSD and anxiety.
The company exercised its option to exclusively license SPC-14, an Alzheimer’s therapeutic, from Columbia University under the same 2021 framework. This agreement secures worldwide rights for Silo Pharma to further develop, manufacture, and commercialize SPC-14 on a global scale.
The company awarded AmplifyBio with a contract for an investigational new drug, enabling a large animal GLP study of its lead asset, SPC-15.
The company entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. Resyca is a joint venture between Bespak Group and Medspray Pharma which manufactures the formulation-specific microchip-based spray system chosen by Silo for its lead candidate SPC-15. The plan is intended to support the development, clinical formulation, and stability of a previously announced investigational new drug, enabling large animal GLP study of SPC-15. As part of an existing exclusive license agreement with Medspray Pharma, one of joint venture members of Resyca, Silo holds exclusive rights to Medspray’s spray mist technology for use with multiple indications including PTSD.
The company entered into an agreement with WuXi AppTec, a leading global contract research organization in Hong Kong, for a preclinical small animal study of SPU-16, a central nervous system homing peptide targeting multiple sclerosis. The company is advancing the development of the SPU-16 liposomal homing peptide through a commercial evaluation license and option agreement with the University of Maryland, Baltimore. The study will examine the organ/tissue specificity of the SPU-16 peptide in an experimental autoimmune encephalomyelitis protocol.
The company announced a new agreement with Sever Pharma Solutions for scale-up extrusion of the Company’s SP-26 ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. Sever Pharma Solutions will continue with analytical testing of the ketamine hydrochloride polymer implants using the optimal time-released, dose-controlled formulation previously selected by Silo for continuing pre-clinical studies.
The company announced a collaboration agreement with Kymanox for specialized design and development of a subcutaneous insertion device for SP-26, the Company’s ketamine-loaded implant therapeutic targeting fibromyalgia and chronic pain. Kymanox will conduct an initial proof-of-concept design phase followed by full system prototype and feasibility testing to determine optimal insertion depth in tissue.
2025
The company was awarded US Patent No. 17/954,864 titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.”
The company entered into a service agreement with medical technology provider Resyca for a drug-device study of the formulation-specific microchip-based nasal spray system used in its lead asset SPC-15.
Columbia University received a notice of allowance for US Patent No. 12,329,726, titled ‘Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,’ which is exclusively licensed by the company including in the licensing of SPC-15.
The company started a strategic 50/50 joint venture with Hoth Therapeutics to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the US Department of Veterans Affairs that was co-developed by the VA and Emory University. The therapeutic platform centers on glial cell line-derived neurotrophic factor, a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. Protected under US Patent No. 10,052,362, the platform targets multiple high-burden conditions, including non-alcoholic fatty liver disease, type 2 diabetes and central obesity.
The company appointed crypto infrastructure pioneer Corwin Yu to launch institutional Bitcoin, Ethereum and Solana treasury platform.
The company announced the publication of preclinical research for its Alzheimer’s disease therapeutic, SPC-14, in Alzheimer’s Research & Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD. The study, titled “Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease,” details research methods and results indicating that the combined administration of (R,S)-ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD.
IP Australia granted patent number 2020271839 to Silo’s research and licensing partner Columbia University for the invention titled “Prophylactic efficacy of serotonin 4 receptor agonists against stress” exclusively licensed to Silo by Columbia University through SPC-15. This event was followed by the same in Japan by the Japan Patent Office.
The company made their first purchases of Ethereum and Solana.
The company engaged Fireblocks, an enterprise platform for building blockchain applications and managing digital asset operations, as the custodian for its institutional crypto treasury platform.
The company made their first purchase of ResearchCoin, which is the native token of ResearchHub. This was followed by the first purchase of Bitcoin.
The company selected Allucent, a global full-service clinical research organization, to support its final preparations and planned submission of its investigational new drug application to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD.
2026
The Japan Patent Office issued a notice of allowance for SPC-15 titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behavior, and Anxiety-Like Behavior,” the allowance covers both composition and method claims.
The company announced a share buyback program up to $1 million of the company’s common stock.
The European Patent Office issued a notice of intent to grant a patent for the company’s exclusively licensed PTSD prevention therapy. Titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” the allowed claims cover methods of preventing stress-induced fear and depressive-like behaviors using serotonin 4 (5-HT4) receptor agonists, expanding the company’s intellectual property protection across major European markets.
The company announced a strategic business expansion into AI technology as a second line of business resulting from its recent purchase of the assets of Qwikagents.ai, an AI platform designed to support the deployment of autonomous AI agents. Followed by the purchase, QwikAgents joined the NVIDIA Developer Program as well as the AMD AI Developer Program.